Hazardous or Poisonous Substance
Medtronic’s PillCam Genius SB Completes First Patient Procedure for GI Diagnostics
Medtronic, PillCam Genius SB, Capsule Endoscopy, GI Diagnostics, At-Home Ingestion, Telehealth
Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens
Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder
Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months
CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.
Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments
Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.
Dr. Reddy’s Recalls Over 300,000 Bottles of Thyroid Medication Due to Carcinogen Contamination
Dr. Reddy’s, thyroid drug recall, carcinogen contamination, pharmaceutical safety, FDA regulations
FDA Approves Protega’s 10 mg Abuse-Deterrent Opioid Roxybond for Pain Management
FDA approval, Protega Pharmaceuticals, Roxybond, abuse-deterrent opioid, pain management, SentryBond technology
Icon, Irish CRO Giant, Announces Layoffs Following Disappointing Q3 Performance
Icon, layoffs, Q3 performance, Irish CRO, biotech industry
Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval
Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative
Psyence Biomed to Acquire Clairvoyant Therapeutics, Expanding Psilocybin-Based Therapeutic Pipeline
Psilocybin, Psyence Biomed, Clairvoyant Therapeutics, Acquisition, Alcohol Use Disorder (AUD), Clinical Trials, Psychedelic Therapeutics
FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research
MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.